Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
NEW DRUG APPLICATION OF OT-502 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that the new drug application for OT-502 (DEXYCU®, Shishu (视姝®), dexamethasone intraocular suspension), a new drug for the treatment of postoperative ocular inflammation, has been approved by the Center for Drug Evaluation of the National Medical Products Administration (the "**NMPA**") of the People's Republic of China (the "**PRC**") recently.

OT-502 (DEXYCU®, Shishu (视姝®), dexamethasone intraocular suspension) is a single-dose, sustained-release suspension of dexamethasone, a corticosteroid, for the treatment of postoperative ocular inflammation. To date, OT-502 is the first and only single-dose, sustained-release intraocular steroid for the treatment of postoperative inflammation that was approved by the United States Food and Drug Administration. The phase III clinical trial of OT-502 was designed as a randomized, double-masked, placebo-controlled, parallel-group, multi-center clinical and pharmacokinetic study to evaluate the efficacy and safety of 9% dexamethasone intraocular suspension in the treatment of post-cataract surgery inflammation, which achieved its primary endpoints in the PRC in April 2024. In September 2024, the new drug application for OT-502 was accepted by the NMPA.

Cautionary Statement: The Company cannot guarantee that OT-502 (DEXYCU®) will ultimately be successfully marketed. **Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, July 2, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.